446 related articles for article (PubMed ID: 19706820)
41. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H; Dutuor A; Fu X; Zhang X
J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
[TBL] [Abstract][Full Text] [Related]
42. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
43. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.
Toth K; Tarakanova V; Doronin K; Ward P; Kuppuswamy M; Locke JE; Dawson JE; Kim HJ; Wold WS
Cancer Gene Ther; 2003 Mar; 10(3):193-200. PubMed ID: 12637940
[TBL] [Abstract][Full Text] [Related]
44. Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy.
Oneal MJ; Trujillo MA; Davydova J; McDonough S; Yamamoto M; Morris JC
Hum Gene Ther; 2012 Sep; 23(9):951-9. PubMed ID: 22694073
[TBL] [Abstract][Full Text] [Related]
45. Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus.
Grünwald GK; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Göke B; Holm PS; Spitzweg C
Gene Ther; 2013 Jun; 20(6):625-33. PubMed ID: 23038026
[TBL] [Abstract][Full Text] [Related]
46. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
Ganesh S; Gonzalez-Edick M; Gibbons D; Ge Y; VanRoey M; Robinson M; Jooss K
Cancer Gene Ther; 2009 May; 16(5):383-92. PubMed ID: 19011598
[TBL] [Abstract][Full Text] [Related]
47. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
48. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
[TBL] [Abstract][Full Text] [Related]
49. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force.
Tresilwised N; Pithayanukul P; Mykhaylyk O; Holm PS; Holzmüller R; Anton M; Thalhammer S; Adigüzel D; Döblinger M; Plank C
Mol Pharm; 2010 Aug; 7(4):1069-89. PubMed ID: 20550160
[TBL] [Abstract][Full Text] [Related]
50. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
51. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.
Wang G; Li G; Liu H; Yang C; Yang X; Jin J; Liu X; Qian Q; Qian W
J Gene Med; 2009 Jun; 11(6):477-85. PubMed ID: 19340843
[TBL] [Abstract][Full Text] [Related]
52. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model.
Ji X; Zhang J; Cheng L; Wei F; Li H; Liu X; Chen X; Li C; Wang Y; Huang Q
Exp Eye Res; 2009 Aug; 89(2):193-9. PubMed ID: 19328781
[TBL] [Abstract][Full Text] [Related]
53. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.
Dias JD; Hemminki O; Diaconu I; Hirvinen M; Bonetti A; Guse K; Escutenaire S; Kanerva A; Pesonen S; Löskog A; Cerullo V; Hemminki A
Gene Ther; 2012 Oct; 19(10):988-98. PubMed ID: 22071969
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
55. Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions.
van Zeeburg HJ; Huizenga A; Brink A; van den Doel PB; Zhu ZB; McCormick F; Brakenhoff RH; van Beusechem VW
Gene Ther; 2010 Dec; 17(12):1517-24. PubMed ID: 20686507
[TBL] [Abstract][Full Text] [Related]
56. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil.
Chu L; Gu J; Sun L; Qian Q; Qian C; Liu X
Gene Ther; 2008 Apr; 15(7):484-94. PubMed ID: 18239605
[TBL] [Abstract][Full Text] [Related]
57. Telomerase-specific virotheranostics for human head and neck cancer.
Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
[TBL] [Abstract][Full Text] [Related]
58. A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy.
Wei N; Fan JK; Gu JF; He LF; Tang WH; Cao X; Liu XY
Biochem Biophys Res Commun; 2009 Oct; 388(2):234-9. PubMed ID: 19653996
[TBL] [Abstract][Full Text] [Related]
59. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
60. Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model.
Saito A; Morishita N; Mitsuoka C; Kitajima S; Hamada K; Lee KM; Kawabata M; Fujisawa M; Shirakawa T
J Gene Med; 2011 Jun; 13(6):353-61. PubMed ID: 21674738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
